U.S. pharma giant copyright scrapped two experimental weight loss products previous year—a at the time-each day tablet, lotiglipron, on account of elevated liver enzymes and also a twice-day-to-day pill, danuglipron, because of potent Unwanted side effects—but CEO Albert Bourla has s